Forty Seven, Inc. (OTC:FTSV)
Industry: PharmaceuticalsMajor

Forty Seven, Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven, Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven, Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Current Quote*
Last: $7.290
Change: -0.250
Book: $2.590
Volume: 31,865

As Of: 08/22 13:17 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol FTSV

Graphs for FTSV

3 Month Graph

6 Month Graph

1 Year Graph